Servier to bag Shire’s cancer businessFrench Servier boosts its cancer drug portfolio acquiring Shire plc’s oncology pipeline, which earned about US$260m last year, for US$2.4bn in cash. more ➔
Germany to boost the bioeconomyShortly before the Global Bioeconomy Summit (19.-20.4.2018) in Berlin will begin, Germany’s new Research Minister Anja Karliczek announced three major initiatives to strengthen the biologisation of the … more ➔
Canopy acquires Czech Annabis Medical sro Canopy Growth Corp. is growing its medical cannabis business in Europe with the acquisition of Czech market leader Annabis Medical sro. more ➔
New Pierre Guerin site in Hildesheim, GermanyMid last year, the company Pierre Guerin has opened a new location in Germany, Hildesheim. more ➔
GSK pass orphan gene therapy assets to Orchard TherapeuticsBritish drug major GlaxoSmithKline (GSK) has passed its orphan autologous cell and gene therapy pipeline including its EU-approved ADA-SCID treatment Strimvelis to British/US Orchard Therapeutics. … more ➔
Alexion in €639m bid for Wilson Therapeutics ABA public offer from orphan drug major Alexion Pharmaceuticals Inc. has been accepted by Wilson Therapeutics’ Board of Directors. Alexion’s SEK232/share bid would total in an acqusition price … more ➔
Novartis enters SMA race acquiring AveXis for US$8.7bn Swiss drug major Novartis has secured a potential stake in the multibillion dollar market of treatments for the orphan genetic muscle disease spinal muscular atrophy (SMA). The company acquired AveXis … more ➔
Blood test predincting Alzheimer’s paves way to earlier therapyA newly developed blood test indicates Alzheimer’s disease on average eight years before the clinical diagnosis. more ➔
Poor investigator brochures: Resarchers call for standardisationHuman drug trials are compromised by poor reporting and potential bias of animal research. German researchers analysed more than 700 preclinical animal studies and investigator brochures provided by … more ➔
Ose and Boehringer ink €1.1bn deal in immunoncologyFrench Ose Immunotherapeutics SA has licenced global commercialisation rights of its preclinical programme OSE-172 to Boehringer Ingelheim which hopes to complement its immunoncology portfolio … more ➔
